SCHEMBL6441971

SCHEMBL6441971

N#Cc1c(OC2CCCCC2)nc(N)nc1-c1ccc2c(c1)OCO2

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 14/20 0.61
ADORA2A P29274 8/20 0.61
ADORA2B P29275 4/20 0.61
TBK1 Q9UHD2 1/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 4/20 0.46
KDM4E B2RXH2 3/20 0.46
USP2 O75604 1/20 0.46
TSHR P16473 1/20 0.46
HPGD P15428 3/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
MAPT P10636 2/20 0.43
ALOX15 P16050 2/20 0.43
POLB P06746 1/20 0.43
ALOX12 P18054 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6445856 0.80 ADORA1 (0.58) ADORA1ADORA2AADORA2B
SCHEMBL6443076 0.80 ADORA1 (0.65) ADORA1ADORA2AADORA2BTBK1ALDH1A1
SCHEMBL6444638 0.80 ADORA1 (0.65) ADORA1ADORA2AADORA2BALDH1A1HSD17B10
SCHEMBL6442645 0.79 ADORA1 (0.61) ADORA1ADORA2AADORA2BTBK1ALDH1A1
SCHEMBL6440616 0.79 ADORA1 (0.73) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6444545 0.77 ADORA1 (0.61) ADORA1ADORA2AADORA2BALDH1A1HSD17B10
SCHEMBL6445033 0.76 ADORA1 (0.69) ADORA1ADORA2AADORA2BALDH1A1KDM4E
SCHEMBL6443434 0.74 ADORA1 (0.58) ADORA1ADORA2AADORA2BHSD17B10KDM4E
SCHEMBL5046621 0.74 ADORA2A (0.55) ADORA1ADORA2AADORA2BALDH1A1HSD17B10
SCHEMBL6441330 0.73 ADORA1 (0.69) ADORA1ADORA2AADORA2BALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA1 3/4885ADORA2A 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.